Gilead HCV Sales Decline In US, But Offset By Global Growth

Strong sales growth continues almost unabated at Gilead Sciences Inc., but the virology powerhouse reported that domestic sales for its hepatitis C drugs actually decreased by 26% year-over-year during the fourth quarter.

Strong sales growth continues almost unabated at Gilead Sciences Inc., but the virology powerhouse reported that domestic sales for its hepatitis C drugs actually decreased by 26% year-over-year during the fourth quarter.

The decline, however, was more than offset by hepatitis C virus (HCV) drug sales growth in the rest of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category